Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Naltrexone And Bupropion

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders

Orexigen Therapeutics, Inc · Phase 2/3 · Completed · Enrollment 3

NCT03946111

ArmPopulationDoseWeeksEstimandWeight change
Naltrexone/BupropionObesity or overweightn/rn/rn/rn/r
PlaceboObesity or overweightn/rn/rn/rn/r